LL-37 has both antimicrobial peptides and immune modulatory effects on the mucosa, encouraging a well-balanced microbiome
Several previously available peptides were placed on the FDA's Category 2 list under section 503A of the Federal Food, Drug, and Cosmetic Act, restricting their use in compounding
doi: 10.3390/pharmaceutics12121230
Neonatal vitamin-responsive epileptic encephalopathies
Any sort of GI problem (including hormone imbalances like thyroid problems) may limit absorption
Dihexa, developed at Washington State University for its synaptic potentiation effects, has attracted particular interest in the tech community, which perhaps explains why the line between Silicon Valley productivity culture and peptide biohacking has become so porous